Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269… Read more
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) - Total Assets
Latest total assets as of June 2025: CN¥3.22 Billion CNY
Based on the latest financial reports, Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) holds total assets worth CN¥3.22 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's total assets of CN¥3.22 Billion consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.6% |
| Accounts Receivable | CN¥27.49 Million | 1.6% |
| Inventory | CN¥44.11 Million | 2.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥429.85 Million | 25.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's current assets represent 58.1% of total assets in 2024, an increase from 38.9% in 2019.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, down from 33.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, a decrease from 52.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 25.0% of total assets.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Dizal (Jiangsu) Pharmaceutical Co. Ltd. A generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is currently not profitable relative to its asset base.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.71 | 1.87 | 9.05 |
| Quick Ratio | 2.66 | 1.81 | 9.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.52 Billion | CN¥ 475.90 Million | CN¥ 1.72 Billion |
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.37 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 14.9% |
| Total Assets | CN¥1.72 Billion |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's assets below their book value (0.65 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's assets grew by 14.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.72 Billion | +14.86% |
| 2023-12-31 | CN¥1.50 Billion | -28.12% |
| 2022-12-31 | CN¥2.08 Billion | -24.18% |
| 2021-12-31 | CN¥2.75 Billion | +125.93% |
| 2020-12-31 | CN¥1.22 Billion | +93.72% |
| 2019-12-31 | CN¥627.36 Million | -- |